Product Name
GLRA1, siRNA
Full Product Name
GLRA1 siRNA (Human)
Product Synonym Names
Glycine receptor subunit alpha-1; Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit
Product Gene Name
GLRA1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P23415
Specificity
GLRA1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human GLRA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of GLRA1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
GLRA1 sirna
siRNA to inhibit GLRA1 expression using RNA interference
Applications Tested/Suitable for GLRA1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for GLRA1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000162.2
[Other Products]
NCBI GenBank Nucleotide #
NM_000171.3
[Other Products]
UniProt Primary Accession #
P23415
[Other Products]
UniProt Secondary Accession #
Q14C77; Q6DJV9; B2R6T3[Other Products]
UniProt Related Accession #
P23415[Other Products]
Molecular Weight
51,693 Da
NCBI Official Full Name
glycine receptor subunit alpha-1 isoform 2
NCBI Official Synonym Full Names
glycine receptor, alpha 1
NCBI Official Symbol
GLRA1 [Similar Products]
NCBI Official Synonym Symbols
STHE; HKPX1
[Similar Products]
NCBI Protein Information
glycine receptor subunit alpha-1
UniProt Protein Name
Glycine receptor subunit alpha-1
UniProt Synonym Protein Names
Glycine receptor 48 kDa subunit; Glycine receptor strychnine-binding subunit
Protein Family
Glycine receptor
UniProt Gene Name
GLRA1 [Similar Products]
UniProt Entry Name
GLRA1_HUMAN
NCBI Summary for GLRA1
The protein encoded by this gene is a subunit of a pentameric inhibitory glycine receptor. The receptor mediates postsynaptic inhibition in the central nervous system. Defects in this gene are a cause of startle disease (STHE), also known as hereditary hyperekplexia or congenital stiff-person syndrome. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]
UniProt Comments for GLRA1
GLRA1: The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing). Defects in GLRA1 are the cause of hyperekplexia, hereditary, type 1 (HKPX1). A neurologic disorder characterized by muscular rigidity of central nervous system origin, particularly in the neonatal period, and by an exaggerated startle response to unexpected acoustic or tactile stimuli. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Glycine receptor (TC 1.A.9.3) subfamily. GLRA1 sub- subfamily. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, multi-pass; Transporter, ion channel; Transporter; Membrane protein, integral
Chromosomal Location of Human Ortholog: 5q32
Cellular Component: postsynaptic membrane; intracellular membrane-bound organelle; integral to plasma membrane; integral to membrane; plasma membrane; cell junction; external side of plasma membrane
Molecular Function: protein binding; transmitter-gated ion channel activity; extracellular-glycine-gated chloride channel activity; glycine binding; taurine binding
Biological Process: regulation of action potential; startle response; synaptic transmission, glycinergic; righting reflex; acrosome reaction; chloride transport; neurological control of breathing; ***** walking behavior; regulation of inhibitory postsynaptic membrane potential; neuromuscular process controlling posture; regulation of membrane potential; muscle contraction; visual perception; negative regulation of transmission of nerve impulse; neuropeptide signaling pathway; ion transport; transmembrane transport
Disease: Hyperekplexia, Hereditary 1
Research Articles on GLRA1
1. Self-declared ethnicity can predict gene-screening outcomes. Cultural practices influence the inheritance patterns and a Caucasian founder is postulated for R271 mutations.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
